US › Healthcare

MaxCyte Inc (MXCT)

US · Healthcare · Medical Devices

$1.11+3.74%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$9.7M
Revenue YoY
-7.1%
Net profit
$-4.8M
Profit YoY
+53.7%
EPS
$-0.04
EPS estimate
$-0.07
Net margin
-49.2%

EPS came in at -0.04 against a street estimate of -0.07 — a beat of 31.7%.

Key statistics

Market cap
$114.6M
Forward P/E
0.0
P/B
0.67
Book value
$1.57
EPS (TTM)
$-0.37
52-week high
$2.15
52-week low
$0.64
50-day MA
$1.18
200-day MA
$1.17
Beta
1.49

Analyst view

Analysts rate MaxCyte Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $4.11.

Shareholding

Insiders
1.59%
Institutions
68.72%

Largest institutional holders

FundStake
BlackRock Inc8.21%
Capricorn Fund Managers Ltd7.65%
Vanguard Group Inc5.17%
Vitruvian Partners4.71%
Vanguard Capital Management, LLC3.72%
Morgan Stanley - Brokerage Accounts3.44%
Mudita Advisors LLP3.15%
BNP Paribas Investment Partners SA2.59%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for MaxCyte Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.